INTUITIVE SURGICAL INC (IUI1.DE) Fundamental Analysis & Valuation

FRA:IUI1 • US46120E6023

Current stock price

413.65 EUR
-10.05 (-2.37%)
Last:

This IUI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. IUI1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year IUI1 was profitable.
  • IUI1 had a positive operating cash flow in the past year.
  • IUI1 had positive earnings in each of the past 5 years.
  • IUI1 had a positive operating cash flow in each of the past 5 years.
IUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFIUI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 13.96%, IUI1 belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
  • The Return On Equity of IUI1 (16.02%) is better than 87.69% of its industry peers.
  • IUI1 has a Return On Invested Capital of 13.95%. This is amongst the best in the industry. IUI1 outperforms 89.23% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for IUI1 is in line with the industry average of 10.72%.
  • The last Return On Invested Capital (13.95%) for IUI1 is above the 3 year average (12.43%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROIC 13.95%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
IUI1.DE Yearly ROA, ROE, ROICIUI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With an excellent Profit Margin value of 28.38%, IUI1 belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of IUI1 has grown nicely.
  • IUI1's Operating Margin of 29.35% is amongst the best of the industry. IUI1 outperforms 96.92% of its industry peers.
  • IUI1's Operating Margin has improved in the last couple of years.
  • The Gross Margin of IUI1 (66.00%) is better than 73.85% of its industry peers.
  • In the last couple of years the Gross Margin of IUI1 has remained more or less at the same level.
Industry RankSector Rank
OM 29.35%
PM (TTM) 28.38%
GM 66%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
IUI1.DE Yearly Profit, Operating, Gross MarginsIUI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IUI1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so IUI1 is still creating some value.
  • The number of shares outstanding for IUI1 has been reduced compared to 1 year ago.
  • Compared to 5 years ago, IUI1 has more shares outstanding
  • IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IUI1.DE Yearly Shares OutstandingIUI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
IUI1.DE Yearly Total Debt VS Total AssetsIUI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

2.2 Solvency

  • An Altman-Z score of 41.47 indicates that IUI1 is not in any danger for bankruptcy at the moment.
  • IUI1 has a better Altman-Z score (41.47) than 100.00% of its industry peers.
  • IUI1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 41.47
ROIC/WACC1.39
WACC10.04%
IUI1.DE Yearly LT Debt VS Equity VS FCFIUI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 4.87 indicates that IUI1 has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.87, IUI1 belongs to the top of the industry, outperforming 96.92% of the companies in the same industry.
  • A Quick Ratio of 3.96 indicates that IUI1 has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 3.96, IUI1 belongs to the best of the industry, outperforming 96.92% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.87
Quick Ratio 3.96
IUI1.DE Yearly Current Assets VS Current LiabilitesIUI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. IUI1.DE Growth Analysis

3.1 Past

  • IUI1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.83%, which is quite impressive.
  • Measured over the past years, IUI1 shows a very strong growth in Earnings Per Share. The EPS has been growing by 21.42% on average per year.
  • The Revenue has grown by 20.51% in the past year. This is a very strong growth!
  • Measured over the past years, IUI1 shows a quite strong growth in Revenue. The Revenue has been growing by 18.22% on average per year.
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%

3.2 Future

  • Based on estimates for the next years, IUI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.58% on average per year.
  • IUI1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.90% yearly.
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IUI1.DE Yearly Revenue VS EstimatesIUI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
IUI1.DE Yearly EPS VS EstimatesIUI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

1

4. IUI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 53.51, the valuation of IUI1 can be described as expensive.
  • Based on the Price/Earnings ratio, IUI1 is valued a bit more expensive than the industry average as 61.54% of the companies are valued more cheaply.
  • Compared to an average S&P500 Price/Earnings ratio of 25.70, IUI1 is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 46.73, the valuation of IUI1 can be described as expensive.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of IUI1 indicates a slightly more expensive valuation: IUI1 is more expensive than 69.23% of the companies listed in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 23.84. IUI1 is valued rather expensively when compared to this.
Industry RankSector Rank
PE 53.51
Fwd PE 46.73
IUI1.DE Price Earnings VS Forward Price EarningsIUI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IUI1 is valued a bit more expensive than the industry average as 67.69% of the companies are valued more cheaply.
  • IUI1's Price/Free Cash Flow ratio is a bit more expensive when compared to the industry. IUI1 is more expensive than 60.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 68.1
EV/EBITDA 45.45
IUI1.DE Per share dataIUI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The excellent profitability rating of IUI1 may justify a higher PE ratio.
  • A more expensive valuation may be justified as IUI1's earnings are expected to grow with 14.52% in the coming years.
PEG (NY)3.7
PEG (5Y)2.5
EPS Next 2Y14.34%
EPS Next 3Y14.52%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IUI1.DE Dividend Analysis

5.1 Amount

  • No dividends for IUI1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IUI1.DE Fundamentals: All Metrics, Ratios and Statistics

INTUITIVE SURGICAL INC

FRA:IUI1 (3/13/2026, 7:00:00 PM)

413.65

-10.05 (-2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)01-22
Earnings (Next)04-20
Inst Owners88.53%
Inst Owner ChangeN/A
Ins Owners0.45%
Ins Owner ChangeN/A
Market Cap146.90B
Revenue(TTM)10.06B
Net Income(TTM)2.86B
Analysts78.1
Price Target527.49 (27.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.28%
Min EPS beat(2)9.85%
Max EPS beat(2)18.71%
EPS beat(4)4
Avg EPS beat(4)10.81%
Min EPS beat(4)3.05%
Max EPS beat(4)18.71%
EPS beat(8)8
Avg EPS beat(8)11.52%
EPS beat(12)12
Avg EPS beat(12)8.73%
EPS beat(16)14
Avg EPS beat(16)6.39%
Revenue beat(2)2
Avg Revenue beat(2)2.19%
Min Revenue beat(2)2.17%
Max Revenue beat(2)2.22%
Revenue beat(4)4
Avg Revenue beat(4)1.83%
Min Revenue beat(4)1.09%
Max Revenue beat(4)2.22%
Revenue beat(8)5
Avg Revenue beat(8)1.43%
Revenue beat(12)7
Avg Revenue beat(12)0.96%
Revenue beat(16)9
Avg Revenue beat(16)0.46%
PT rev (1m)-1.16%
PT rev (3m)0.59%
EPS NQ rev (1m)-0.08%
EPS NQ rev (3m)0.27%
EPS NY rev (1m)0%
EPS NY rev (3m)3.07%
Revenue NQ rev (1m)-0.07%
Revenue NQ rev (3m)0.45%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)1.02%
Valuation
Industry RankSector Rank
PE 53.51
Fwd PE 46.73
P/S 16.85
P/FCF 68.1
P/OCF 55.97
P/B 9.52
P/tB 9.73
EV/EBITDA 45.45
EPS(TTM)7.73
EY1.87%
EPS(NY)8.85
Fwd EY2.14%
FCF(TTM)6.07
FCFY1.47%
OCF(TTM)7.39
OCFY1.79%
SpS24.54
BVpS43.47
TBVpS42.52
PEG (NY)3.7
PEG (5Y)2.5
Graham Number86.95
Profitability
Industry RankSector Rank
ROA 13.96%
ROE 16.02%
ROCE 16.01%
ROIC 13.95%
ROICexc 20.73%
ROICexgc 21.4%
OM 29.35%
PM (TTM) 28.38%
GM 66%
FCFM 24.75%
ROA(3y)12.67%
ROA(5y)12.15%
ROE(3y)14.56%
ROE(5y)13.99%
ROIC(3y)12.43%
ROIC(5y)12.44%
ROICexc(3y)18.4%
ROICexc(5y)18.81%
ROICexgc(3y)19.07%
ROICexgc(5y)19.65%
ROCE(3y)14.27%
ROCE(5y)14.28%
ROICexgc growth 3Y2.03%
ROICexgc growth 5Y0.92%
ROICexc growth 3Y2.86%
ROICexc growth 5Y2.05%
OM growth 3Y4.58%
OM growth 5Y3.73%
PM growth 3Y10.12%
PM growth 5Y3.12%
GM growth 3Y-0.72%
GM growth 5Y0.11%
F-Score8
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 79.72%
Cap/Sales 5.36%
Interest Coverage 250
Cash Conversion 83.46%
Profit Quality 87.21%
Current Ratio 4.87
Quick Ratio 3.96
Altman-Z 41.47
F-Score8
WACC10.04%
ROIC/WACC1.39
Cap/Depr(3y)178.7%
Cap/Depr(5y)155.64%
Cap/Sales(3y)11.2%
Cap/Sales(5y)9.67%
Profit Quality(3y)61.68%
Profit Quality(5y)71.87%
High Growth Momentum
Growth
EPS 1Y (TTM)21.83%
EPS 3Y23.94%
EPS 5Y21.42%
EPS Q2Q%14.48%
EPS Next Y14.45%
EPS Next 2Y14.34%
EPS Next 3Y14.52%
EPS Next 5Y13.58%
Revenue 1Y (TTM)20.51%
Revenue growth 3Y17.39%
Revenue growth 5Y18.22%
Sales Q2Q%18.76%
Revenue Next Year15.88%
Revenue Next 2Y14.86%
Revenue Next 3Y14.57%
Revenue Next 5Y12.9%
EBIT growth 1Y25.34%
EBIT growth 3Y22.76%
EBIT growth 5Y22.63%
EBIT Next Year35.56%
EBIT Next 3Y21.57%
EBIT Next 5Y17.26%
FCF growth 1Y91.03%
FCF growth 3Y37.49%
FCF growth 5Y16.85%
OCF growth 1Y25.49%
OCF growth 3Y26.68%
OCF growth 5Y15.34%

INTUITIVE SURGICAL INC / IUI1.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INTUITIVE SURGICAL INC?

ChartMill assigns a fundamental rating of 7 / 10 to IUI1.DE.


Can you provide the valuation status for INTUITIVE SURGICAL INC?

ChartMill assigns a valuation rating of 1 / 10 to INTUITIVE SURGICAL INC (IUI1.DE). This can be considered as Overvalued.


Can you provide the profitability details for INTUITIVE SURGICAL INC?

INTUITIVE SURGICAL INC (IUI1.DE) has a profitability rating of 9 / 10.


Can you provide the financial health for IUI1 stock?

The financial health rating of INTUITIVE SURGICAL INC (IUI1.DE) is 9 / 10.